ZW427 / Zymeworks - LARVOL DELTA

ZW427, a Ly6E-targeting antibody drug conjugate bearing a novel pan-RAS inhibitor payload for the treatment of RAS mutated cancers (AACR 2026) - "The pan-RASi ADC platform that has been developed shows encouraging tolerability in mice and an imminent toxicology study of ZW427 in non-human primates will further define its safety profile. Overall, the data supports the potential of ZW427 as a novel, highly differentiated therapeutic agent against Ly6E-expressing RAS mutant cancer indications."

ADC • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • LY6E

ZW427, a Ly6E-targeting antibody-drug conjugate bearing a novel pan-RAS inhibitor payload for the treatment of RAS mutated cancers (GlobeNewswire) - "Zymeworks presents new preclinical data at AACR 2026....Robust anti-tumor activity observed across CRC, PDAC, and NSCLC xenograft models with a range of Ly6E expression. Targeted delivery enables sustained RAS inhibition in tumors with reduced activity in normal tissues such as skin and colon. Favorable tolerability observed in rodents and non-human primates at exposures exceeding projected efficacious doses."

Preclinical • Colorectal Cancer • Non Small Cell Lung Cancer • Pancreatic Ductal Adenocarcinoma